Q Fang, P F Xu, F Cao, Z Zhao, X R Zhang, D Wu, C Y Chen, Z M Li, F Han, X K Liu
{"title":"[PD-1抑制剂联合纳布紫杉醇和顺铂在局部晚期下咽鳞癌新辅助治疗中的疗效】。]","authors":"Q Fang, P F Xu, F Cao, Z Zhao, X R Zhang, D Wu, C Y Chen, Z M Li, F Han, X K Liu","doi":"10.3760/cma.j.cn115330-20231016-00152","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To assess the efficacy of neoadjuvant treatment with PD-1 (programmed cell death protein 1) inhibitors combined with paclitaxel (albumin-conjugated) and cisplatin (TP regimen) for locally advanced hypopharyngeal squamous cell carcinoma and laryngeal organ function preservation. <b>Methods:</b> Data of 53 patients, including 51 males and 2 females, aged 38-70 years old, who were diagnosed with locally advanced hypopharyngeal squamous carcinoma confirmed by histology and enhanced CT at the Cancer Prevention and Control Center of Sun Yat-sen University during the initial treatment from January 1, 2019 to January 15, 2023, were retrospectively analyzed. All patients received neoadjuvant therapy with PD-1 inhibitors combined with albumin-bound paclitaxel (260 mg/m<sup>2</sup>) and cisplatin (60 mg/m<sup>2</sup>) for 3 to 4 cycles. The main outcome measures were larynx dysfunction-free survival (LDFS), overall survival (OS), and progression-free survival (PFS). Survival curves were plotted using the Kaplan-Meier method, and Cox multifactorial analysis was further performed if Cox univariate analysis was statistically significant. <b>Results:</b> The overall efficiency was 90.6% (48/53). The 1-year and 2-year LDFS rates were 83.8% (95%<i>CI</i>: 74.0% to 94.8%) and 50.3% (95%<i>CI</i>: 22.1% to 91.6%), the 1-year and 2-year OS rates were 95.2% (95%<i>CI</i>: 88.9% to 100.0%) and 58.2% (95%<i>CI</i>: 25.6% to 81.8%), and the 1-year and 2-year PFS rates were 83.9% (95%<i>CI</i>: 74.2% to 94.9%) and 53.5% (95%<i>CI</i>: 32.1% to 89.1%). Adverse events associated with the neoadjuvant therapy were mainly myelosuppression (45.3%), gastrointestinal reactions (37.7%) and hypothyroidism (20.8%). <b>Conclusion:</b> The neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma using PD-1 inhibitors combined with paclitaxel and cisplatin can provide with a higher survival rate with a improved laryngeal organ function preservation rate.</p>","PeriodicalId":23987,"journal":{"name":"Chinese journal of otorhinolaryngology head and neck surgery","volume":"59 7","pages":"750-757"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Efficacy of PD-1 inhibitors combined with nab-paclitaxel and cisplatin in the neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma].\",\"authors\":\"Q Fang, P F Xu, F Cao, Z Zhao, X R Zhang, D Wu, C Y Chen, Z M Li, F Han, X K Liu\",\"doi\":\"10.3760/cma.j.cn115330-20231016-00152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To assess the efficacy of neoadjuvant treatment with PD-1 (programmed cell death protein 1) inhibitors combined with paclitaxel (albumin-conjugated) and cisplatin (TP regimen) for locally advanced hypopharyngeal squamous cell carcinoma and laryngeal organ function preservation. <b>Methods:</b> Data of 53 patients, including 51 males and 2 females, aged 38-70 years old, who were diagnosed with locally advanced hypopharyngeal squamous carcinoma confirmed by histology and enhanced CT at the Cancer Prevention and Control Center of Sun Yat-sen University during the initial treatment from January 1, 2019 to January 15, 2023, were retrospectively analyzed. All patients received neoadjuvant therapy with PD-1 inhibitors combined with albumin-bound paclitaxel (260 mg/m<sup>2</sup>) and cisplatin (60 mg/m<sup>2</sup>) for 3 to 4 cycles. The main outcome measures were larynx dysfunction-free survival (LDFS), overall survival (OS), and progression-free survival (PFS). Survival curves were plotted using the Kaplan-Meier method, and Cox multifactorial analysis was further performed if Cox univariate analysis was statistically significant. <b>Results:</b> The overall efficiency was 90.6% (48/53). The 1-year and 2-year LDFS rates were 83.8% (95%<i>CI</i>: 74.0% to 94.8%) and 50.3% (95%<i>CI</i>: 22.1% to 91.6%), the 1-year and 2-year OS rates were 95.2% (95%<i>CI</i>: 88.9% to 100.0%) and 58.2% (95%<i>CI</i>: 25.6% to 81.8%), and the 1-year and 2-year PFS rates were 83.9% (95%<i>CI</i>: 74.2% to 94.9%) and 53.5% (95%<i>CI</i>: 32.1% to 89.1%). Adverse events associated with the neoadjuvant therapy were mainly myelosuppression (45.3%), gastrointestinal reactions (37.7%) and hypothyroidism (20.8%). <b>Conclusion:</b> The neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma using PD-1 inhibitors combined with paclitaxel and cisplatin can provide with a higher survival rate with a improved laryngeal organ function preservation rate.</p>\",\"PeriodicalId\":23987,\"journal\":{\"name\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"volume\":\"59 7\",\"pages\":\"750-757\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn115330-20231016-00152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of otorhinolaryngology head and neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn115330-20231016-00152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Efficacy of PD-1 inhibitors combined with nab-paclitaxel and cisplatin in the neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma].
Objective: To assess the efficacy of neoadjuvant treatment with PD-1 (programmed cell death protein 1) inhibitors combined with paclitaxel (albumin-conjugated) and cisplatin (TP regimen) for locally advanced hypopharyngeal squamous cell carcinoma and laryngeal organ function preservation. Methods: Data of 53 patients, including 51 males and 2 females, aged 38-70 years old, who were diagnosed with locally advanced hypopharyngeal squamous carcinoma confirmed by histology and enhanced CT at the Cancer Prevention and Control Center of Sun Yat-sen University during the initial treatment from January 1, 2019 to January 15, 2023, were retrospectively analyzed. All patients received neoadjuvant therapy with PD-1 inhibitors combined with albumin-bound paclitaxel (260 mg/m2) and cisplatin (60 mg/m2) for 3 to 4 cycles. The main outcome measures were larynx dysfunction-free survival (LDFS), overall survival (OS), and progression-free survival (PFS). Survival curves were plotted using the Kaplan-Meier method, and Cox multifactorial analysis was further performed if Cox univariate analysis was statistically significant. Results: The overall efficiency was 90.6% (48/53). The 1-year and 2-year LDFS rates were 83.8% (95%CI: 74.0% to 94.8%) and 50.3% (95%CI: 22.1% to 91.6%), the 1-year and 2-year OS rates were 95.2% (95%CI: 88.9% to 100.0%) and 58.2% (95%CI: 25.6% to 81.8%), and the 1-year and 2-year PFS rates were 83.9% (95%CI: 74.2% to 94.9%) and 53.5% (95%CI: 32.1% to 89.1%). Adverse events associated with the neoadjuvant therapy were mainly myelosuppression (45.3%), gastrointestinal reactions (37.7%) and hypothyroidism (20.8%). Conclusion: The neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma using PD-1 inhibitors combined with paclitaxel and cisplatin can provide with a higher survival rate with a improved laryngeal organ function preservation rate.
期刊介绍:
Chinese journal of otorhinolaryngology head and neck surgery is a high-level medical science and technology journal sponsored and published directly by the Chinese Medical Association, reflecting the significant research progress in the field of otorhinolaryngology head and neck surgery in China, and striving to promote the domestic and international academic exchanges for the purpose of running the journal.
Over the years, the journal has been ranked first in the total citation frequency list of national scientific and technical journals published by the Documentation and Intelligence Center of the Chinese Academy of Sciences and the China Science Citation Database, and has always ranked first among the scientific and technical journals in the related fields.
Chinese journal of otorhinolaryngology head and neck surgery has been included in the authoritative databases PubMed, Chinese core journals, CSCD.